beef
Auto Added by WPeMatico
This Y Combinator startup is taking lab-grown meat upscale with elk, lamb and Wagyu beef cell lines
Last week a select group of 20 employees and guests gathered at an event space on the San Francisco Bay, and, while looking out at the Bay Bridge, dined on a selection of choice elk sausages, Wagyu meatloaf and lamb burgers — all of which were grown from a petri dish.
The dinner was a coming out party for Orbillion Bio, a new startup pitching today in Y Combinator’s latest demo day, that’s looking to take lab-grown meats from the supermarket to high-end, bespoke butcher shops.
Instead of focusing on pork, chicken and beef, Orbillion is going after so-called heritage meats — the aforementioned elk, lamb and Wagyu beef to start.
By focusing on more expensive-end products, Orbillion doesn’t have as much pressure to slash costs as dramatically as other companies in the cellular meat market, the thinking goes.
But there’s more to the technology than its bougie beef, elite elk and luscious lamb meat.
“Orbillion uses a unique accelerated development process producing thousands of tiny tissue samples, constantly iterating to find the best tissue and media combinations,” according to Holly Jacobus, whose firm, Joyance Partners, is an early investor in Orbillion. “This is much less expensive and more efficient than traditional methods and will enable them to respond quickly to the impressive demand they’re already experiencing.”
The company runs its multiple cell lines through a system of small bioreactors. Orbillion couples that with a high throughput screening and machine learning software system to build out a database of optimized tissue and media combinations. “The key to making lab grown meat work scalably is choosing the right cells cultured in the most efficient way possible,” Jacobus wrote.
Orbillion is co-founded by a deeply technical and highly experienced team of executives that’s led by Patricia Bubner, a former researcher at the German pharmaceutical giant Boehringer Ingelheim. Joining Bubner is Gabriel Levesque-Tremblay, a former director of the American Institute of Chemical Engineers, who was a post-doc at Berkeley with Bubner and serves as the company’s chief technology officer. Rounding out the senior leadership is Samet Yildirim, the chief operating officer and a veteran executive of Boehringer Ingelheim (he actually served as Bubner’s boss).
Orbillion Bio co-founders Gabriel Levesque-Tremblay, CTO; Patricia Bubner, CEO; and Samet Yildirim, COO. Image Credit: Orbillion Bio
For Bubner, the focus on heritage meats is as much a function of her background growing up in rural Austria as it is about economics. A longtime, self-described foodie and a nerd, Bubner went into chemistry because she ultimately wanted to apply science to the food business. And she wants Orbillion to make not just meat, but the most delicious meats.
It’s an aim that fits with how many other companies have approached the market when they’re looking to commercialize a novel technology. Higher-end products, or products with unique flavor profiles that are unique to the production technologies available, are more likely to be commercially viable sooner than those competing with commodity products. Why focus on angus beef when you can focus on a much more delicious breed of animal?
For Bubner, it’s not just about making a pork replacement, it’s about making the tastiest pork replacement.
“I’m just fascinated and can see the future in us being able to further change the way we produce food to be more efficient,” she said. “We’re at this inflection point. I’m a nerd, I’m a foodie, and I really wanted to use my skills to make a change. I wanted to be part of that group of people that can really have an impact on the way we eat. For me there’s no doubt that a large percentage of our food will be from alternative proteins — plant based, fermentation and lab-grown meat.”
Joining Boehringer Ingelheim was a way for Bubner to become grounded in the world of big bioprocessing. It was preparation for her foray into lab-grown meat, she said.
“We are a product company. Our goal is to make the most flavorful steaks. Our first product will not be whole cuts of steak. The first product is going to be a Wagyu beef product that we plan on putting out in 2023,” Bubner said. “It’s a product that’s going to be based on more of a minced product. Think Wagyu sashimi.”
To get to market, Bubner sees the need not just for a new approach to cultivating choice meats, but a new way of growing other inputs as well, from the tissue scaffolding needed to make larger cuts that resemble traditional cuts of meat, or the fats that will need to be combined with the meat cells to give flavor.
That means there are still opportunities for companies like Future Fields, Matrix Meats and Turtle Tree Scientific to provide inputs that are integrated into the final, branded product.
Bubner’s also thinking about the supply chain beyond her immediate potential partners in the manufacturing process. “Part of my family were farmers and construction workers and the others were civil engineers and architects. I hold farmers in high respect… and think the people who grow the food and breed the animals don’t get recognition for the work that they do.”
She envisions working in concert with farmers and breeders in a kind of licensing arrangement, potentially, where the owners of the animals that produce the cell lines can share in the rewards of their popularization and wider commercial production.
That also helps in the mission of curbing the emissions associated with big agribusiness and breeding and raising livestock on a massive scale. If you only need a few animals to make the meat, you don’t have the same environmental footprint for the farms.
“We need to make sure that we don’t make the mistakes that we did in the past that we only breed animals for yield and not for flavor,” said Bubner.
Even though the company is still in its earliest days, it already has one letter of intent, with one of San Francisco’s most famous butchers. Guy Crims, also known as “Guy the Butcher,” has signed a letter of intent to stock Orbillion Bio’s lab-grown Wagyu in his butcher shop, Bubner said. “He’s very much a proponent of lab-grown meat.”
Now that the company has its initial technology proven, Orbillion is looking to scale rapidly. It will take roughly $3.5 million for the company to get a pilot plant up and running by the end of 2022, and that’s in addition to the small $1.4 million seed round the company has raised from Joyant and firms like VentureSouq.
“The way I see an integrated model working later on is to have the farmers be the breeders of animals for cultivated meat. That can reduce the number of cows on the planet to a couple of hundred thousand,” Bubner said of her ultimate goal. “There’s a lot of talking about if you do lab-grown meat you want to put me out of business. It’s not like we’re going to abolish animal agriculture tomorrow.”
Image Credit: Getty Images
Powered by WPeMatico
The Not Company, a maker of plant-based meat and dairy substitutes in Chile, will soon be worth $250M
The Not Company, Latin America’s leading contender in the plant-based meat and dairy substitute market, is about to close on an $85 million round of funding that would value it at $250 million, according to sources familiar with the company’s plans.
The latest round of funding comes on the heels of a series of successes for the Santiago-based business. In the two years since NotCo launched on the global stage, the company has expanded beyond its mayonnaise product into milk, ice cream and hamburgers. Other products, including a chicken meat substitute, are also on the product roadmap, according to people familiar with the company.
NotCo is already selling several products in Chile, Argentina and Latin America’s largest market — Brazil — and has signed a blockbuster deal with Burger King to be the chain’s supplier of plant-based burgers. It’s in this Burger King deal that NotCo’s approach to protein formulation is paying dividends, sources said. The company is responsible for selling 48 sandwiches per store per day in the locations where it’s supplying its products, according to one person familiar with the data. That figure outperforms Impossible Foods per-store sales, the person said.
NotCo is also now selling its burgers in grocery stores in Argentina and Chile. And while the company is not break-even yet, sources said that by December 2021 it could be — or potentially even cash flow positive.
NotCo co-founders Karim Pichara, Matias Muchnick and Pablo Zamora. Image Credit: The Not Company
With the growth both in sales and its diversification into new products, it’s little wonder that investors have taken note.
Sources said that the consumer brand-focused private equity firm L Catterton Partners and the Biz Stone-backed Future Positive were likely investors in the new financing round for the company. Previous investors in NotCo include Bezos Expeditions, the personal investment firm of Amazon founder Jeff Bezos; the London-based CPG investment firm, The Craftory; IndieBio; and SOS Ventures.
Alternatives to animal products are a huge (and still growing) category for venture investors. Earlier this month Perfect Day closed on a second tranche of $160 million for that company’s latest round of financing, bringing that company’s total capital raised to $361.5 million, according to Crunchbase. Perfect Day then turned around and launched a consumer food business called the Urgent Company.
These recent rounds confirm our reporting in Extra Crunch about where investors are focusing their time as they try to create a more sustainable future for the food industry. Read more about the path they’re charting.
Meanwhile, large food chains continue to experiment with plant-based menu items and push even further afield into cell-based meat using cultures from animals. KFC recently announced that it would be expanding its experiment with Beyond Meat’s chicken substitute in the U.S. — and would also be experimenting with cultured meat in Moscow.
Behind all of this activity is an acknowledgement that consumer tastes are changing, interest in plant-based diets are growing, and animal agriculture is having profound effects on the world’s climate.
As the website ClimateNexus notes, animal agriculture is the second-largest contributor to human-made greenhouse gas emissions after fossil fuels. It’s also a leading cause of deforestation, water and air pollution and biodiversity loss.
There are 70 billion animals raised annually for human consumption, which occupy one-third of the planet’s arable and habitable land surface, and consume 16% of the world’s freshwater supply. Reducing meat consumption in the world’s diet could have huge implications for reducing greenhouse gas emissions. If Americans were to replace beef with plant-based substitutes, some studies suggest it would reduce emissions by 1,911 pounds of carbon dioxide.
Powered by WPeMatico
Dutch startup Meatable is developing lab-grown pork and has $10 million in new financing to do it
Meatable, the Dutch startup developing cruelty-free technologies for manufacturing cultured meat, is pivoting to pork production as a swine flu epidemic ravages one quarter of the world’s pork supply — and has raised $10 million in financing to support its new direction.
When the company unveiled its technology last year, it was one of several companies working on the production of meat derived from animal cells — a method of meat production that theoretically has a far smaller carbon emissions footprint and is better for the environment than traditional animal farming.
At the time, it was one of several companies — including Memphis Meats, Future Meat Technologies, Aleph Farms, HigherSteaks and many, many pursuing technologies — to bring cultured beef to market. Now, as pork prices rise globally, Meatable becomes one of the first companies to publicly shift gears and turn its attention to the other white meat.
That’s not the only way the company is setting itself apart from its peers in the market. Meatable is also an early claimant to a commercially viable, patented process for manufacturing meat cells without the need to kill an animal as a prerequisite for cell differentiation and growth.
Other companies have relied on fetal bovine serum or Chinese hamster ovaries to stimulate cell division and production, but Meatable says it has developed a process where it can sample tissue from an animal, revert that tissue to a pluripotent stem cell, then culture that cell sample into muscle and fat to produce the pork products that palates around the world crave.
“We know which DNA sequence is responsible for moving an early-stage cell to a muscle cell,” says Meatable chief executive Krijn De Nood.
To pursue its new path, the company has raised $7 million from a slew of angel and institutional investors and a $3 million grant from the European Commission . Angel investors include Taavet Hinrikus, the chief executive and co-founder of TransferWise, and Albert Wenger, a managing partner at the New York-based venture firm Union Square Ventures.
Meatable’s De Nood says that the new cash will be used to accelerate the development of its prototype. The small-scale bioreactor the company had initially targeted for development in 2021 will now be ready by 2020 and the company is hoping to have an industry-scale plant online manufacturing thousands of kilograms of meat by 2025, according to De Nood.
Industrial farming is responsible for between 14% and 18% of the greenhouse gas emissions linked to global climate change and Meatable argues that cultured (lab-grown) meat has the potential to use 96% less water and 99% less land than industrial farming. Powering facilities using renewable energy could further reduce emissions associated with meat production, according to Meatable.
Powered by WPeMatico
Novameat has a platform for 3D-printing steaks and has new money to take it to market
Novameat, a Spanish startup looking to accelerate the development of alternative proteins across the meat aisle, has gotten a boost in the form of new investment capital from the leading foodtech investment firm, New Crop Capital.
Founded by biomedical engineering expert Giuseppe Scionti, Novameat builds on Scionti’s decade of research as an assistant professor in bioengineering at the Polytechnic University of Catalonia, the University College of London, Chalmers University and Polytechnic University of Milan.
The company first came to fame with the production of the world’s first 3D-printed plant-based beefsteak in 2018 and will use the new funds from New Crop Capital to further develop its platform for accelerating the development of meats like steak, chicken breasts and other fibrous textured meat replacements.
The company has developed a new scaffolding technology that mimics the texture, appearance, nutritional and sensorial properties of fibrous meats like beefsteaks, chicken breasts and fish filets.
Scionti sees the technology as the next step in the development of plant-based and lab-cultured alternatives to traditional proteins. While many clean meat and plant-based food companies have managed to take ground meat replacements to market with similar taste and textural qualities to the real thing, steaks and cuts of muscle meat have proven harder to replicate.
Novameat potentially solves that problem.
“While I was researching on regenerating animal tissues through bioprinting technologies for biomedical and veterinary applications, I discovered a way to bio-hack the structure of the native 3D matrix of a variety of plant-based proteins to achieve a meaty texture,” said Scionti, in a statement.
The core of Novameat’s technology is a customized printer that enables companies to create the kinds of fibrous tissues needed to make a steak. “We are providing the equipment, the machinery, under a licensing agreement to these companies,” says Scionti. “Plant-based meat manufacturers have access to something that creates the texture and taste of a steak.”
Traditional extrusion technologies are not capable of using the ingredients from Beyond Meat or Impossible Foods to print a steak, but Novameat’s founder argues that his technology can.
The technology was promising enough to attract the attention of New Crop Capital, arguably one of the most seasoned investors in the expanding market of meat replacement. The venture firm’s portfolio includes Memphis Meat, Beyond Meat, Kite Hill, Geltor, Good Dot, Aleph Farms, Supermeat, Mosa Meat, New Wave and Zero Egg.
“We think the global food supply chain is broken and we are focused on fixing one of those challenges, which is animal protein,” says New Crop Capital’s Dan Altschuler Malek. “We see that there is an opportunity to shift consumer behavior to reduce their consumption of animal protein products to products that are at the price point that people will pay.”
Novameat can help reduce costs, Malek thinks, because it speeds up the time to create meat substitutes.
Scionti says the company’s micro-extrusion technology enables companies to get a three-dimensional structure without having to go through an incubation period that can take a significant amount of time and increase costs.
“Novameat’s bioprinting-based technology provides a flexible and tunable method of producing plant-based meat, with the utility to create different textures from a wide variety of ingredients, all within a single piece of meat,” he said. “Low and high-moisture extruders are the primary method currently used to restructure plant proteins to create the texture of meat. While extrusion works well for some applications, this method may not be ideal for mimicking all types of animal meat. Alternative technologies like Novameat’s give plant-based meat manufacturers a wider array of tools to mimic all types of meat and seafood,” said Good Food Institute Director of Science and Technology David Welch, in a statement.
Powered by WPeMatico